SEC For	m 4 FORM	4	UNITED	STA	TES	s se					CHAI	NGE C	оммі	SSION]
Section 16. Form 4 or Form 5 obligations may continue. See				d purs	Washington, D.C. 20549 IT OF CHANGES IN BENEFICIAL OWNER I pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB A OMB Number: Estimated aver hours per respo			3235-0287	
1. Name and Address of Reporting Person [*] Lund-Hansen Torben						2. Issuer Name and Ticker or Trading Symbol <u>Y-mAbs Therapeutics, Inc.</u> [YMAB]								eck all applic Directo	able)	10% Owne		
(Last) (First) (Middle) C/O Y-MABS THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/14/2021									X below) below) SVP & CTO				pecity
230 PARK AVENUE SUITE 3350 (Street) NEW YORK NY 10169					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	,	(Zip)	-Deriv	ativ	e Se	curities	s Ac	quired. D	isnos	sed o	f. or Be	neficial					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action	ction 2A. Deemed Execution Dat			ar) 3. 4. Sector Dispos		Securit sposed	rities Acquired (A) ed Of (D) (Instr. 3, 4		5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Table II - [(uired, Dis , options	spose		(D) or Bene	eficially	(Instr. 3 a				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	Code (Ins				6. Date Exercisat Expiration Date (Month/Day/Year)		able and 7. Title and A of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)		e s dly g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisable	Expira Date	ration	Title	Amount or Number of Shares	iber				
Employee Stock Option (right to buy) ⁽¹⁾	\$15.73	12/14/2021			A		32,000		(2)	12/14	1/2031	Common stock	32,000	\$0	32,00	10	D	

Explanation of Responses:

1. Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.

2. The stock option shall vest and become exercisable as to 25% of the shares subject to the option on December 14, 2022, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

/s/ Torben Lund-Hansen 12/15/2021 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.